{"id":78413,"date":"2024-07-31T10:08:42","date_gmt":"2024-07-31T08:08:42","guid":{"rendered":"https:\/\/www.veeva.com\/eu\/?p=78413"},"modified":"2025-07-09T15:50:18","modified_gmt":"2025-07-09T13:50:18","slug":"3-ways-emerging-biotech-and-pharma-leaders-can-use-data-to-level-the-playing-field","status":"publish","type":"post","link":"https:\/\/pantheon.veeva.com\/eu\/blog\/3-ways-emerging-biotech-and-pharma-leaders-can-use-data-to-level-the-playing-field\/","title":{"rendered":"3 Ways Emerging Biotech and Pharma Leaders Can Use Data to Level the Playing Field"},"content":{"rendered":"

Data shows that 70% of key opinion leaders (KOLs) only engage with one biopharma<\/a>, making it difficult for emerging companies to compete with established industry leaders. ADVANZ PHARMA <\/a>and Idorsia<\/a> share how you can level the playing field using deep KOL data to support product launches, enter new therapy areas, and optimize congress strategies.<\/p>\n

Mitigate launch risk through early KOL engagement<\/h2>\n

Over a third of all drugs fail to meet market expectations<\/a> in their first year. And, while you can\u2019t control every aspect of a launch, early engagement with KOLs during pre-launch can help mitigate risks.<\/p>\n

Recent analysis<\/a> shows that engaging with KOLs before launch is associated with 1.5 times greater treatment adoption over the first six months post-launch. Engagement with KOLs in the pre-launch phase establishes a foundational relationship, setting you up for long-term growth.<\/p>\n

Knowing the key decision makers along the patient journey is important when building pre-launch engagement strategies. The KOL data that you leverage should identify established KOLs, emerging experts, and digital opinion leaders (DOLs) to broaden the reach of scientific messages.<\/p>\n

As Angela Smart, director, global medical excellence and operations at ADVANZ PHARMA explains, \u201cGone are the days where medical can just focus on top-tier scientific thought leaders. Stakeholders are increasing in breadth as the decision-makers along a patient pathway can now include external experts, healthcare practitioners, payers, and patient organisations as an example.\u201d <\/p>\n

Navigate new therapy areas with deep KOL data<\/h2>\n

Harnessing deep KOL data can help you hit the ground running when entering new therapeutic areas of interest. Baptiste Omont, senior director of commercial and medical systems at Idorsia, shares, \u201cWhen it came time to launch a product in chronic insomnia, an area where nothing new has happened in the last 20 years, we wondered, where can we find the data, who do we engage with, and where do we start?\u201d<\/p>\n

Idorsia first focused on building awareness. Using Veeva Link Key People<\/a>, Omont and his colleagues identified and engaged with the most relevant KOLs and DOLs in the area of chronic insomnia. <\/p>\n

Data can also inform resource planning and headcount strategy as you explore new therapy areas. \u201cYou need to evaluate the complexity of the molecule you’re bringing to market, the complexity of the disease area, and the competitive environment,\u201d says Smart. \u201cAll of this data combined helps calculate the resources medical needs to enter a new therapy area.\u201d <\/p>\n

ADVANZ PHARMA plans to launch multiple products across different therapy areas over the next few years, and real-time KOL data is essential to keeping their field teams agile. \u201cOur field teams need to pivot quickly between different therapy areas. With Link Key People, they can map out and extract lists of the top external experts that they want to work with,\u201d shares Smart. <\/p>\n

Maximize medical congress impact with limited resources<\/h2>\n

Access to deep data for medical congress planning can help you find the most relevant congresses, identify and engage relevant contributors, and capture critical insights. But, with limited resources and lean teams, it can be difficult to effectively prepare.<\/p>\n

As you seek to maximize medical congress impact<\/a>, providing your teams with real-time intelligence on congresses and attendees can significantly reduce time spent on manual research and spreadsheet data upkeep. Link Key People led ADVANZ PHARMA to identify local congresses they weren\u2019t previously aware of, enhancing scientific engagement with increasingly relevant stakeholders.<\/p>\n

Often, dedicated teams aren\u2019t in place to manage congress strategy, and as Smart explains, \u201cUsually congresses are managed by marketing and medical affairs on top of their day job. That’s why streamlining the congress planning process is crucial.\u201d <\/p>\n

From international conferences to local events, Link Key People helps teams quickly find detailed information on relevant congresses, understand their reach, and view agendas, key contributors, and competitive activities. <\/p>\n

Learn how ADVANZ PHARMA<\/a> and Idorsia<\/a> enable better KOL engagements with Link Key People. <\/p>\n","protected":false},"excerpt":{"rendered":"

ADVANZ PHARMA and Idorsia share their experiences utilizing market data for launch, entering new therapy areas, and building congress strategy.<\/p>\n","protected":false},"author":392,"featured_media":67101,"comment_status":"closed","ping_status":"closed","sticky":true,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"product":[998],"area":[973],"coauthors":[1577],"class_list":["post-78413","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","product-deep-kol-data-link","area-data","blog-area-commercial","blog-product-data","blog-html-content-yes"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/posts\/78413"}],"collection":[{"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/users\/392"}],"replies":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/comments?post=78413"}],"version-history":[{"count":7,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/posts\/78413\/revisions"}],"predecessor-version":[{"id":85685,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/posts\/78413\/revisions\/85685"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/media\/67101"}],"wp:attachment":[{"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/media?parent=78413"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/categories?post=78413"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/tags?post=78413"},{"taxonomy":"product","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/product?post=78413"},{"taxonomy":"area","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/area?post=78413"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/pantheon.veeva.com\/eu\/wp-json\/wp\/v2\/coauthors?post=78413"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}